Home Journals Articles Updates About
CN
image
收藏切换
The recent advance of direct anti-HBV drug candidates in clinical trials
收藏切换
PDF
Mei WANG1, Lin-yue LIU1, Chuan-ju LI1, Jun LIU2, *, Hai-yong JIA1, *
Acta Pharmaceutica Sinica | 2022, 57(10) : 2972 - 2984
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(10): 2972-2984
• Special Reports Ⅰ: New Targets, New Strategies for Drug Discovery and Advances in Antiviral Drug Research •
The recent advance of direct anti-HBV drug candidates in clinical trials
Full
Mei WANG1, Lin-yue LIU1, Chuan-ju LI1, Jun LIU2, *, Hai-yong JIA1, *
Affiliations
  • 1. School of Pharmacy, Weifang Medical University, Weifang 261053, China
  • 2. School of Nursing, Weifang Medical University, Weifang 261053, China
Published: 2022-10-12 doi: 10.16438/j.0513-4870.2022-0318
Outline
收藏切换

Hepatitis B virus (HBV) infection is a serious global public health problem. Chronic hepatitis B virus infection can cause health problems such as cirrhosis, liver metabolism disorders and hepatocellular carcinoma. Nucloes(t)ide analogues and interferon drugs used to treat chronic HBV infection do not completely eradicate covalently closed circular DNA (cccDNA) and integrated genome of HBV DNA, so that they cannot achieve the functional cure of chronic HBV infection. Currently, a series of drugs targeting the phases of HBV lifecycle and immunomodulators have entered clinical trials. Here, we review the current status of the therapeutic drugs as well as the recent advance of direct antiviral agents.

hepatitis B virus  /  drug target  /  nucloes(t)ide analogue  /  direct antiviral agent
Mei WANG, Lin-yue LIU, Chuan-ju LI, Jun LIU, Hai-yong JIA. The recent advance of direct anti-HBV drug candidates in clinical trials[J]. Acta Pharmaceutica Sinica, 2022 , 57 (10) : 2972 -2984 . DOI: 10.16438/j.0513-4870.2022-0318
Appendix
Less
Year 2022 volume 57 Issue 10
PDF
170
74
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0318
  • Receive Date：2022-03-15
  • Online Date：2025-12-24
  • Published：2022-10-12
Article Data
Affiliations
History
  • Received：2022-03-15
  • Revised：2022-04-08
Funding
Affiliations
    1. School of Pharmacy, Weifang Medical University, Weifang 261053, China
    2. School of Nursing, Weifang Medical University, Weifang 261053, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0318
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House